JP Morgan Put 160 CHKP 15.11.2024/ DE000JK1RB69 /
6/18/2024 8:16:19 AM | Chg.-0.040 | Bid10:00:39 PM | Ask10:00:39 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.850EUR | -4.49% | - Bid Size: - |
- Ask Size: - |
Check Point Software... | 160.00 USD | 11/15/2024 | Put |
GlobeNewswire
3:29 PM
OFFSITE, LLC Announces Strategic Partnership with Check Point Software to Enhance Enterprise Securit...
GlobeNewswire
9:00 AM
Precision-Panc Team Open the PRIMUS-006 Study, a Novel Combination of IMM-101, Gemcitabine and Pembr...
GlobeNewswire
6/14
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritini...
GlobeNewswire
6/14
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Tria...
GlobeNewswire
6/12
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at ...
GlobeNewswire
6/12
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in ...
GlobeNewswire
6/12
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck ...
GlobeNewswire
6/11
Check Point Software Simplifies Cloud Application Security with AI-Powered WAFaaS
GlobeNewswire
6/11
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-I...
GlobeNewswire
6/10
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire
6/10
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FD...
GlobeNewswire
6/6
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Reco...
GlobeNewswire
6/6
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European...
GlobeNewswire
6/6
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Beha...
GlobeNewswire
6/5
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positiv...
GlobeNewswire
6/5
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire
6/4
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losse...
GlobeNewswire
6/4
Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
GlobeNewswire
6/4
CKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investor...
GlobeNewswire
6/3
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
GlobeNewswire
6/3
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the...
GlobeNewswire
6/3
DEADLINE ALERT for CKPT, OCGN, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class...